ARDX
HEALTHCAREArdelyx Inc
AI Insight
What's Moving ARDX Today?
No stock-specific AI insight has been generated for ARDX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.56$8.40
$6.18
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-0.24
Dividend Yield—
Dividend / Share—
ROE-39.5%
Profit Margin-13.6%
Debt / Equity—
Trading
Volume3.1M
Avg Volume (10D)—
Shares Outstanding247.0M
ARDX News
23 articles- Ardelyx Stock Up 70%: What to Know About This $490,000 Insider TransactionMotley Fool·Jun 23, 2026
- What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?Yahoo Finance·Jun 23, 2026
- Ardelyx (ARDX) Stock Valuation Check After Recent Share Price VolatilityYahoo Finance·Jun 12, 2026
- Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within ReachMarketbeat·Jun 4, 2026
- ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’Stocktwits·Jun 3, 2026
- Should You Buy Ardelyx (ARDX)?Yahoo Finance·May 30, 2026
- ARDX (NASDAQ: ARDX) reports 5,355 RSUs vest; insider sales notedStock Titan·May 20, 2026
- Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026The Manila Times·May 19, 2026
- Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's ChangedYahoo Finance·May 9, 2026
- Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue GuidanceYahoo Finance·May 7, 2026
- Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical MeetingsYahoo Finance·May 7, 2026
- Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter ReportYahoo Finance·May 2, 2026
- Ardelyx Inc (ARDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic InvestmentsYahoo Finance·May 1, 2026
- Ardelyx, Inc. Q1 2026 Earnings Call SummaryMoby·May 1, 2026
- Ardelyx (ARDX) Q1 2026 Earnings TranscriptMotley Fool·Apr 30, 2026
- Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·Apr 30, 2026
- Ardelyx Q1 Earnings Call HighlightsMarketbeat·Apr 30, 2026
- Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key MetricsYahoo Finance·Apr 30, 2026
- Ardelyx Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·Apr 30, 2026
- Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical MeetingsYahoo Finance·Apr 27, 2026
- Is Ardelyx (ARDX) Offering Value After Recent Share Price Swings And DCF Estimate GapYahoo Finance·Apr 25, 2026
- Ardelyx President and CEO Sells 41,000 Shares for $243,000The Motley Fool·Apr 3, 2026
- Rajani Dinavahi, MD, Appointed Chief Medical Officer of ArdelyxGlobeNewswire Inc.·Apr 1, 2026
All 23 articles loaded
Price Data
Open$6.35
Previous Close$6.37
Day High$6.47
Day Low$6.17
52 Week High$8.40
52 Week Low$3.56
52-Week Range
$3.56$8.40
$6.18
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-0.24
Dividend Yield—
Dividend / Share—
ROE-39.5%
Profit Margin-13.6%
Debt / Equity—
Trading
Volume3.1M
Avg Volume (10D)—
Shares Outstanding247.0M
About Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—